Experimental CAR-T therapy targets tough blood cancers in early trial
NCT ID NCT07365059
First seen Jan 29, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or refractory plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed to attack cancer cells. The main goals are to check safety and see if the treatment shrinks tumors, while also studying how long the cells last in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL DYSCRASIAS are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GPRC5D CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat plasma cell disorders like multiple myeloma.
What could go wrong
This is a very early, small trial (18 people) testing safety first. The therapy may not work or could cause serious side effects like immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.